Organogenesis Holdings Inc.
ORGODrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ORGO Earnings Report
FQ end 2026-06 | Call: 2026-08-06 15:00:00
How ORGO's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Amniotic Suspension Allograft | Phase 3 | Knee Osteoarthritis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Organogenesis Holdings Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Organogenesis Holdings Inc.'s (ORGO) pipeline across Phase 3. Its lead program is Amniotic Suspension Allograft (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Organogenesis Holdings Inc.'s next FDA catalyst?→
Organogenesis Holdings Inc.'s (ORGO) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ORGO biotech catalysts?→
Add ORGO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Organogenesis Holdings Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.